United Therapeutics (UTHR) to Release Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) is expected to announce its earnings results before the market opens on Wednesday, February 19th. Analysts expect the company to announce earnings of $6.54 per share and revenue of $734.74 million for the quarter.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $370.58 on Tuesday. United Therapeutics has a fifty-two week low of $211.61 and a fifty-two week high of $417.82. The business has a 50-day simple moving average of $362.00 and a two-hundred day simple moving average of $359.42. The firm has a market cap of $16.55 billion, a price-to-earnings ratio of 16.27, a price-to-earnings-growth ratio of 0.92 and a beta of 0.57.

Insider Activity

In other news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $348.06, for a total transaction of $3,480,600.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $896,950.62. This represents a 79.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the sale, the executive vice president now owns 36,710 shares in the company, valued at $13,743,122.70. The trade was a 17.34 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 121,864 shares of company stock worth $44,516,965. 11.90% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. UBS Group upped their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Argus upped their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. HC Wainwright upped their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Finally, TD Cowen boosted their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $382.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.